PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

about

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Item

http://www.wikidata.org/entity/Q61938289

description

clinical trial

@en

klinisch onderzoek

@nl

name

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

@en

type

Item

label

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

@en

prefLabel

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

@en

P1132

135

http://www.w3.org/2001/XMLSchema#decimal

P1476

PARP Inhibition After Preopera ...... osier Oncology Group BRE09-146

@en

P17

Ameeriga Ütisriigiq

P2899

http://www.w3.org/2001/XMLSchema#decimal

P3098

NCT01074970

http://www.w3.org/2001/XMLSchema#string

P31

clinical trial

P4844

cisplatin

rucaparib

P580

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P582

2018-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6099

phase II clinical trial

P6153

University of Tennessee

Indiana University – Purdue University Indianapolis

Virginia Oncology Associates

Comprehensive Cancer Centers of Nevada

P8005

completed